emerald trial: an analysis of key biomarkers and patient subgroups
Published 1 month ago • 29 plays • Length 23:00Download video MP4
Download video MP3
Similar videos
-
23:00
emerald trial: an analysis of key biomarkers and patient subgroups
-
2:21
updated results by duration of prior cdk4/6i in the met setting of the phase iii emerald trial
-
39:55
new checkpoints and biomarkers
-
6:00
current and emerging biomarkers of response to immunotherapeutic regimens
-
16:10
emerald study lead to the elacestrant fda approval - oncbrothers in discussion w/ dr. aditya bardia
-
1:33
biomarker analysis of the clear & keynote-426 trials in arcc
-
0:30
the impact of the emerald trial results based on duration of prior cdk4/6i in the metastatic setting
-
34:23
new rogers mitochondrial toxin theory of cancer june 2024
-
21:19
estrogen receptors & her2/neu receptors in breast cancer (a tutorial from oster oncology)
-
3:24
'tumors just vanished': cancer patients now in remission after drug trial
-
8:30
evaluating biomarkers at work in nsclc
-
1:20
emerald™ laser - peace, balance, healing | erchonia® lasers
-
12:00
exploring the role of biomarkers in lung cancer treatment
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
33:23
advances in biomarker testing - summit 2021
-
9:00
adjuvant treatment for braf stage iii melanoma: a case study to weigh ici versus targeted therapies
-
16:58
assessing immune biomarkers of response to anthracyclines in breast cancer
-
3:38
emerald-1 trial in hcc
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
1:08
the decisiondx®-melanoma test complements current melanoma staging
-
6:00
balancing the scales: the complementary roles of rcts and rwe in modern healthcare